
Homegrown blood cancer drug PHI-101 wins ODD in Europe following US
Pharos iBbio said Tuesday that PHI-101, its next-generation indigenous acute myeloid leukemia drug, has received orphan drug designation from the European Medicines Agency (EMA). The designation is noteworthy, as it officially recognizes the innovative …